PrIMe researcher receives grant to improve safety of pain medications for cats
May 1, 2016
Cats are the most common pet in the United States. Every year, thousands of cats unnecessarily suffer from pain and inflammation when they could have benefitted from treatment with non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam. This is because relative to most dogs and humans, cats are more likely to experience serious side effects from NSAIDs, limiting safe and effective inflammation and pain control in this species. Understanding the effects of NSAIDs on cellular metabolism in cats will help unveil the mechanism underlying their predisposition to serious side effects relative to other species and open the way to substantial advances in the treatment of inflammation and pain in these animals. In this study we will determine the effects of chronic meloxicam administration on cellular metabolite profiles in cat plasma and urine. We will apply an untargeted metabolomics approach that will allow us to identify currently unknown metabolite changes that could explain why cats are predisposed to adverse effects of the NSAID meloxicam.